CellMax Life Inc (合度精密生物科技) yesterday launched a blood-testing service in Taiwan that focuses on screening for early-stage cancer.
The company’s flagship product, CellMax CRC-Protect, is a multi-biomarker blood test aimed at the early detection of colorectal cancer.
The product has been used by more than 500 patients at a number of local hospitals, including Linkou Chang Gung Memorial Hospital (林口長庚紀念醫院).
“We aim to transform cancer care away from expensive, intractable late stages to early, more treatable stages,” CellMax Life co-founder and chief operating officer Atul Sharan told a news conference in Taipei yesterday.
Much of the biotechnology sector focuses on expensive late-stage drugs that might not be accessible in developing countries, while survival rates for patients with late-stage cancer diminish rapidly, Sharan added.
The company’s proprietary CMx technology platform screens for cancer by detecting traces of circulating early-stage tumor cells that are shed from the primary tumor site into the bloodstream, CellMax science team chief Shao Hung-jen (邵宏仁) said.
Abnormal cells should be detected by the screening product before they turn into precancerous cells and metastasize, Shao said.
The platform uses a biomimetic, lipid-bilayer coated microfluidic chip to identify circulating tumor cells cells in patients’ blood samples, Shao said.
As the test requires a blood sample, it is an attractive option for patients who are averse to fecal occult blood tests, stool samples or colonoscopies, Shao said.
However, the test is not intended to replace existing examinations, but is designed to be used as an additional diagnostic tool by physicians, Shao said.
A woman said in a testimonial video that after using a CellMax screening product and consulting her physician, she agreed to have intestinal surgery that removed eight polyps and minimized her chances of contracting colon cancer.
Chao recommended that people who are at high risk of developing colon cancer undergo annual screening, adding that each of the firm’s tests costs about NT$15,000.
CellMax’s other products include testing of genetic risk, liquid biopsies and recurrence monitoring.
The company also announced US$9 million in series A-1 venture funding to scale commercial operations of its blood test product portfolio.
The funding was led by Silicon Valley-based Artiman Ventures and several Taiwanese venture investors, including Acer founder and former chairman Stan Shih (施振榮).
The company has so far accumulated US$14 million in venture capital.
CAUTIOUS RECOVERY: While the manufacturing sector returned to growth amid the US-China trade truce, firms remain wary as uncertainty clouds the outlook, the CIER said The local manufacturing sector returned to expansion last month, as the official purchasing managers’ index (PMI) rose 2.1 points to 51.0, driven by a temporary easing in US-China trade tensions, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The PMI gauges the health of the manufacturing industry, with readings above 50 indicating expansion and those below 50 signaling contraction. “Firms are not as pessimistic as they were in April, but they remain far from optimistic,” CIER president Lien Hsien-ming (連賢明) said at a news conference. The full impact of US tariff decisions is unlikely to become clear until later this month
GROWING CONCERN: Some senior Trump administration officials opposed the UAE expansion over fears that another TSMC project could jeopardize its US investment Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is evaluating building an advanced production facility in the United Arab Emirates (UAE) and has discussed the possibility with officials in US President Donald Trump’s administration, people familiar with the matter said, in a potentially major bet on the Middle East that would only come to fruition with Washington’s approval. The company has had multiple meetings in the past few months with US Special Envoy to the Middle East Steve Witkoff and officials from MGX, an influential investment vehicle overseen by the UAE president’s brother, the people said. The conversations are a continuation of talks that
CHIP DUTIES: TSMC said it voiced its concerns to Washington about tariffs, telling the US commerce department that it wants ‘fair treatment’ to protect its competitiveness Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reiterated robust business prospects for this year as strong artificial intelligence (AI) chip demand from Nvidia Corp and other customers would absorb the impacts of US tariffs. “The impact of tariffs would be indirect, as the custom tax is the importers’ responsibility, not the exporters,” TSMC chairman and chief executive officer C.C. Wei (魏哲家) said at the chipmaker’s annual shareholders’ meeting in Hsinchu City. TSMC’s business could be affected if people become reluctant to buy electronics due to inflated prices, Wei said. In addition, the chipmaker has voiced its concern to the US Department of Commerce
STILL LOADED: Last year’s richest person, Quanta Computer Inc chairman Barry Lam, dropped to second place despite an 8 percent increase in his wealth to US$12.6 billion Staff writer, with CNA Daniel Tsai (蔡明忠) and Richard Tsai (蔡明興), the brothers who run Fubon Group (富邦集團), topped the Forbes list of Taiwan’s 50 richest people this year, released on Wednesday in New York. The magazine said that a stronger New Taiwan dollar pushed the combined wealth of Taiwan’s 50 richest people up 13 percent, from US$174 billion to US$197 billion, with 36 of the people on the list seeing their wealth increase. That came as Taiwan’s economy grew 4.6 percent last year, its fastest pace in three years, driven by the strong performance of the semiconductor industry, the magazine said. The Tsai